炎症性肠病经济负担的研究进展

Research progress in the economic burden of inflammatory bowel disease

炎症性肠病(IBD)是一种病因不明、病情反复、迁延不愈的疾病,可累及多个器官及系统。当前,IBD发病呈年轻化趋势,因病情反复影响工作甚至导致失业,耗费大量的社会和医疗资源。生物制剂用于IBD的治疗已有20余年,其增加了治疗的选择性。但同时也有研究发现生物制剂的使用是增加IBD经济负担的主要因素之一。而生物类似物较生物制剂在优化成本-效益方面具有显著优势,应用前景良好。本文通过总结国内外IBD卫生经济学的研究现状,旨在为加强疾病管理和改善患者生存质量提供经济学依据。

Inflammatory bowel disease(IBD)has recurrent and protracted course with unknown etiology and it can affect multiple organs and systems.At present,IBD patients tends to be younger,and the recurrent disease affects work,even resulting in unemployment,and consumes a lot of social and medical resources.Having been used for the treatment of IBD for more than 20 years,biologics increase the selectivity of treatment,but at the same time,current research has found that the use of biologics is one of the main factors increasing the economic burden of IBD.Compared with biologics,biosimilars have significant advantages in optimizing cost⁃benefit and have good application prospects.By summarizing the current research status of IBD health economics at home and abroad,this review aims to provide an economic basis for strengthening disease management and improving the quality of life of patients.